Science, strategy, and capital allocation: three interlocking dimensions.

We advise on the decisions that determine whether assets advance, get redesigned, or stop. Before those decisions become expensive.

• Target selection and tractability assessment for biologics and vaccine programs
• Protein design and engineering: de novo antibody design, antigen stabilisation, developability strategy
• Pipeline prioritisation integrating scientific, operational, and commercial considerations
• Scientific due diligence for partnerships, in-licensing, and investment decisions
• Go/no-go advisory grounded in molecular-level understanding and stage-gate realities
• Integration of AI/ML and bioinformatics into protein engineering and vaccine discovery workflows

Sound scientific decisions do not automatically produce sound organisational ones. Translating pipeline progress into portfolio direction, and portfolio direction into team performance requires operating at a different level.

• Function-building and team reorganisation, including capability gaps and role design
• Cross-functional alignment between discovery, development, CMC, and commercial
• Disciplined Agile implementation for R&D environments
• Partnership strategy for CROs, spinouts, and translational programs moving toward commercial readiness
• Onboarding and scientific alignment through the SynMinds Series

Scientific and strategic clarity only create value when they connect to the decisions that allocate resources: which programs to fund, which partnerships to pursue, and how to tell the story to those who control the capital.

• Scientific and commercial materials for investors, grant committees, and strategic partners
• Competitive landscape analysis and market positioning grounded in scientific credibility
• Business development support, including client-facing program management and stakeholder engagement
• Operational tools and workflow automation to free focus for higher-value scientific and strategic work

A common language for high-performing teams.

Misalignment in biopharma often stems from divergent mental models across biology, computation, and operations. The SynMinds Series is a collection of concise, structured booklets that reduce that friction, establishing a shared foundation that accelerates decision-making and team performance.

Available upon request. Tailored versions for specific team contexts can be discussed.